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Escherichia coli is undoubtedly the most studied bacterial species in microbiology. However, other members of the genus do exist, with the most widely accepted species being Escherichia albertii ([@B1]) and Escherichia fergusonii ([@B2]). Escherichia adecarboxylata, E. blattae, E. hermannii, and E. vulneris were also once considered to be part of the genus but have since been reclassified ([@B3][@B4][@B6]). In 2009, Walk et al. reported the discovery of five genetically distinct "cryptic" lineages of Escherichia spp. that were phenotypically indistinguishable from E. coli ([@B7], [@B8]). As part of our continuing work to expand the observed genomic diversity of E. coli, the genomes of 55 strains belonging to these other lineages and species of Escherichia were sequenced. Many of the strains were previously misidentified as E. coli, demonstrating the need for further study and characterization of these lineages.

Pure cultures of each strain were grown aerobically overnight in Luria-Bertani broth at 37°C. Total genomic DNA was extracted from 1 ml of overnight culture using the DNeasy blood and tissue kit (Qiagen, Hilden, Germany). DNA extractions were performed with the Qiagen QIAcube instrument using the manufacturer's Gram-negative bacteria protocol. Sequencing libraries were prepared with 1 ng of DNA by using the Nextera XT DNA sample prep kit (Illumina, San Diego, CA, USA) and sequenced on either an Illumina MiSeq or NextSeq platform. The resulting paired-end reads were quality controlled using FastQC (Q \> 30) and *de novo* assembled using SPAdes 3.8.2 ([@B9]) or CLC Genomics Workbench 8.2.1 (CLC bio, Aarhus, Denmark).

Depth of coverage for the draft genomes ranged from 21× to 186×, with the genome sizes ranging from 4,006,242 to 5,544,922 bp. The number of contigs ranged from 29 to 333, while the *N*~50~ values ranged from 30,834 to 440,408 bp. Nine strains of E. albertii and two strains of E. fergusonii were sequenced as part of the collection. Preliminary phylogenetic analysis utilizing polymorphisms present within conserved core genes identified one strain, EC7003, as belonging to a new cryptic lineage, which we have designated lineage 6. The remaining 43 strains belong to cryptic lineages 1 through 5, with 10, 1, 3, 4, and 25 strains identified within each lineage, respectively. The strains were screened for the presence of the known or putative virulence factors *aggR*, *eae*, *ipaH*, LT, ST, *stx*~1~, and *stx*~2~. All 55 strains were negative for *aggR*, *ipaH*, and *stx*~1~. Both E. fergusonii strains and all cryptic lineage 2, 3, 4, and 5 strains were negative for all seven factors investigated. All nine E. albertii strains and the cryptic lineage 6 strain EC7003 possess the *eae* adhesin. The cryptic lineage 1 strains are more varied in their profiles, with five strains negative for all seven factors, three strains positive for LT and ST, one strain positive for LT only, and one strain positive for ST and *stx*~2~.
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The draft genome assemblies were deposited in DDBJ/ENA/GenBank through the FDA's GenomeTrakr pipeline under BioProject number [PRJNA230969](https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA230969) with accession numbers [PTRD00000000](https://www.ncbi.nlm.nih.gov/nuccore/PTRD00000000) to [PTTF00000000](https://www.ncbi.nlm.nih.gov/nuccore/PTTF00000000). The versions described in this announcement are the first versions, with the exception of PTSX00000000, which is the second version.
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